Want to see HK:1276 full AI Analyst Report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Ratios
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Ratios
HK:1276's free cash flow for Q3 2026 was $5.57B. For the 2026 fiscal year, HK:1276's free cash flow was decreased by $-1.29B and operating cash flow was $6.86B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.08 | 9.72 | 12.25 | 8.50 | 8.87 |
| Quick Ratio | 7.63 | 9.05 | 11.34 | 7.82 | 8.17 |
| Cash Ratio | 6.43 | 6.83 | 8.12 | 4.15 | 4.01 |
| Solvency Ratio | 1.06 | 1.76 | 1.86 | 1.19 | 1.40 |
| Operating Cash Flow Ratio | 1.76 | 2.04 | 3.01 | 0.35 | 1.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 13.87 | 0.80 | 4.59 |
| Net Current Asset Value | $ 48.30B | $ 33.26B | $ 31.46B | $ 30.42B | $ 32.55B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.02 | 0.04 | 0.03 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.02 | 0.04 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.10 | 1.08 | 1.12 | 1.12 |
| Debt Service Coverage Ratio | 596.72 | 1280.61 | 8.96 | 2.78 | 4.40 |
| Interest Coverage Ratio | 626.53 | 1347.54 | 831.66 | 633.40 | 531.21 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.11 | 0.30 | 0.21 |
| Net Debt to EBITDA | -4.28 | -3.11 | -3.72 | -2.90 | -2.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 86.21% | 86.25% | 84.55% | 83.61% | 84.45% |
| EBIT Margin | 27.58% | 25.64% | 20.48% | 18.68% | 14.63% |
| EBITDA Margin | 30.20% | 28.41% | 23.57% | 21.40% | 16.73% |
| Operating Profit Margin | 28.42% | 26.77% | 21.52% | 19.33% | 14.63% |
| Pretax Profit Margin | 27.53% | 25.62% | 20.45% | 18.65% | 17.35% |
| Net Profit Margin | 24.38% | 22.64% | 18.85% | 18.36% | 17.60% |
| Continuous Operations Profit Margin | 24.40% | 22.64% | 18.75% | 17.93% | 17.42% |
| Net Income Per EBT | 88.56% | 88.38% | 92.19% | 98.43% | 101.43% |
| EBT Per EBIT | 96.86% | 95.72% | 95.05% | 96.51% | 118.63% |
| Return on Assets (ROA) | 11.04% | 12.64% | 9.88% | 9.35% | 11.37% |
| Return on Equity (ROE) | 12.58% | 13.92% | 10.69% | 10.48% | 12.75% |
| Return on Capital Employed (ROCE) | 14.16% | 16.11% | 11.97% | 10.77% | 10.34% |
| Return on Invested Capital (ROIC) | 12.55% | 14.24% | 10.83% | 9.94% | 10.07% |
| Return on Tangible Assets | 12.23% | 14.05% | 10.70% | 9.86% | 11.57% |
| Earnings Yield | 1.85% | 1.93% | 1.36% | 1.26% | 1.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.00 | 4.20 | 3.32 | 2.26 | 3.31 |
| Payables Turnover | 1.92 | 1.96 | 2.79 | 2.38 | 2.21 |
| Inventory Turnover | 1.52 | 1.59 | 1.52 | 1.42 | 1.64 |
| Fixed Asset Turnover | 4.00 | 4.04 | 3.44 | 3.19 | 4.04 |
| Asset Turnover | 0.45 | 0.56 | 0.52 | 0.51 | 0.65 |
| Working Capital Turnover Ratio | 0.84 | 0.91 | 0.81 | 0.76 | 1.01 |
| Cash Conversion Cycle | 123.87 | 129.59 | 218.64 | 264.73 | 167.22 |
| Days of Sales Outstanding | 73.01 | 86.92 | 109.90 | 161.64 | 110.24 |
| Days of Inventory Outstanding | 240.82 | 229.26 | 239.59 | 256.54 | 222.40 |
| Days of Payables Outstanding | 189.96 | 186.59 | 130.85 | 153.45 | 165.43 |
| Operating Cycle | 313.83 | 316.18 | 349.49 | 418.18 | 332.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.93 | 1.25 | 1.34 | 0.23 | 0.85 |
| Free Cash Flow Per Share | 1.42 | 0.92 | 1.08 | -0.13 | 0.53 |
| Dividend Paid and CapEx Coverage Ratio | 2.65 | 2.29 | 3.05 | 0.42 | 1.64 |
| Capital Expenditure Coverage Ratio | 3.79 | 3.77 | 5.15 | 0.64 | 2.69 |
| Operating Cash Flow Coverage Ratio | 259.44 | 107.52 | 12.22 | 0.75 | 3.96 |
| Operating Cash Flow to Sales Ratio | 0.36 | 0.27 | 0.33 | 0.06 | 0.17 |
| Free Cash Flow Yield | 1.99% | 1.66% | 1.95% | -0.23% | 0.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 54.09 | 52.03 | 73.28 | 79.38 | 64.45 |
| Price-to-Sales (P/S) Ratio | 13.15 | 11.74 | 13.82 | 14.58 | 11.34 |
| Price-to-Book (P/B) Ratio | 6.79 | 7.22 | 7.83 | 8.32 | 8.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 50.27 | 60.24 | 51.18 | -426.60 | 103.76 |
| Price-to-Operating Cash Flow Ratio | 37.01 | 44.26 | 41.25 | 245.09 | 65.19 |
| Price-to-Earnings Growth (PEG) Ratio | 2.21 | 1.26 | 8.43 | -4.02 | -2.78 |
| Enterprise Value Multiple | 39.25 | 38.20 | 54.90 | 65.21 | 64.86 |
| Enterprise Value | 417.15B | 323.13B | 326.79B | 338.12B | 336.58B |
| EV to EBITDA | 39.25 | 38.20 | 54.90 | 65.21 | 64.86 |
| EV to Sales | 11.85 | 10.85 | 12.94 | 13.95 | 10.85 |
| EV to Free Cash Flow | 45.32 | 55.70 | 47.93 | -408.41 | 99.24 |
| EV to Operating Cash Flow | 33.37 | 40.92 | 38.63 | 234.64 | 62.36 |
| Tangible Book Value Per Share | 9.44 | 6.89 | 6.56 | 6.37 | 6.71 |
| Shareholders’ Equity Per Share | 10.52 | 7.64 | 7.04 | 6.63 | 6.71 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.12 | 0.08 | 0.04 | -0.00 |
| Revenue Per Share | 5.43 | 4.70 | 3.99 | 3.78 | 4.86 |
| Net Income Per Share | 1.32 | 1.06 | 0.75 | 0.69 | 0.86 |
| Tax Burden | 0.89 | 0.88 | 0.92 | 0.98 | 1.01 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.19 |
| Research & Development to Revenue | 0.22 | 0.24 | 0.22 | 0.23 | 0.22 |
| SG&A to Revenue | 0.23 | 0.26 | 0.28 | 0.29 | 0.47 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.46 | 1.17 | 1.79 | 0.33 | 0.99 |
Currency in HKD
